STOCKHOLM – December 10, 2021 – ContextVision, a medical technology software company specializing in image processing, today announces that at the EGM of ContextVision on Dec 10th, it was resolved that the subsidiary INIFY Laboratories will become an independent company through a distribution of its shares to existing shareholders of ContextVision. The company will build […]
On the 10th of December 2021, ContextVision AB held an Extraordinary General Meeting in Stockholm. The Board’s proposal for a resolution on dividend of all shares in the Company’s wholly-owned subsidiary INIFY Laboratories AB containing the line of business Digital Pathology to the shareholders of ContextVision AB, was approved. No other matters were processed at […]
ContextVision announces Rivent 3D, an evolution in ultrasound medical imaging technology. Rivent 3D is based on the benefits of volumetric processing, strengthened with the capabilities to process powerfully while maintaining a natural appearance.
The shareholders of ContextVision AB, corporate registration number 556377-8900, are hereby invited to attend an extraordinary general meeting on the 10 December, 2021 at 10 a.m CET at ContextVision AB’s office, Klara Norra Kyrkogata 31, 111 22, Stockholm. Right to participate and notification Shareholders who wish to participate in the annual general meeting with the […]
ContextVision today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.
Join us at RSNA 2021 – virtual event, November 28 – December 1 where you will be able to see our latest groundbreaking solutions in image enhancement.
Martin Ingvar, Member of the Board of ContextVision, has on October 21, 2021 purchased 6,000 shares in ContextVision AB at an average price of NOK 22.10 per share. After the transaction, Mr Ingvar holds a total of 12,000 shares in ContextVision AB.
ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.
INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers
ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.
Martin Ingvar, Member of the Board of ContextVision, has on September 1, 2021 purchased 6,000 shares in ContextVision AB at an average price of NOK 24.41 per share. After the transaction, Mr Ingvar holds a total of 6,000 shares in ContextVision AB.